Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients with Myocardial Infarction and No-reflow
NCT ID: NCT02739711
Last Updated: 2025-01-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE4
120 participants
INTERVENTIONAL
2016-07-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction
NCT00976092
IRIS : Use of Implantable Defibrillator in High-risk Patients Early After Acute Myocardial Infarction
NCT00157768
Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome
NCT00373451
Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism
NCT01855139
European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
NCT01087723
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Glycoprotein IIb/IIIa inhibitor
Glycoprotein IIb/IIIa inhibitor administration
Glycoprotein IIb/IIIa inhibitors
Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
Standard therapy
No glycoprotein IIb/IIIa inhibitors
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glycoprotein IIb/IIIa inhibitors
Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Angiographic evidence of no-reflow (Thrombolysis in Myocardial Infarction-flow grade ≤2) after primary percutaneous coronary intervention
* Age ≥18 years
* Informed consent
Exclusion Criteria
* Age ≤18 years
* Known pregnancy, breast-feeding or intend to become pregnant during the study period
* Contraindication for treatment with platelet inhibitors
* Known allergy to glycoprotein IIb/IIIa inhibitors, aspirin, or heparin
* Active peptic gastric or duodenal ulcer
* History of major surgery (including intracranial or intraspinal) \<4 weeks
* Active bleeding or bleeding diathesis
* Stroke \<2 years (ischemic and hemorrhagic)
* Known coagulation defect or relevant thrombocytopenia
* Arteriovenous malformations or aneurysm
* Severe liver insufficiency
* Renal insufficiency requiring dialysis
* Uncontrolled hypertension
* Hypertensive retinopathy
* Vasculitis
* Fibrinolysis \<12 hours
* Contraindication for cardiac magnetic resonance imaging at study entry
* Patients without informed consent
* Participation in another trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Luebeck
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. med. Ingo Eitel
Director, Department of Cardiology/Angiology/Intensive Care Medicine, University Heart Center Luebeck
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Luebeck
Lübeck, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Eitel I, Saraei R, Jurczyk D, Fach A, Hambrecht R, Wienbergen H, Frerker C, Schmidt T, Allali A, Joost A, Marquetand C, Kurz T, Haaf P, Fahrni G, Mueller C, Desch S, Thiele H, Stiermaier T. Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial. Eur Heart J. 2024 Dec 16;45(47):5058-5067. doi: 10.1093/eurheartj/ehae587.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AZ 15-259
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.